Granulomatosis with polyangiitis (GPA), formerly called Wegener’s granulomatosis, is an immune-mediated vasculitis that often involves the nose/sinuses, lungs and kidneys. Confidence is high that possible organ-threatening disease requires prompt assessment; an ANCA blood result alone is not a diagnosis. GPA overview. Treatment is organized around the involved organs, active disease versus damage, and prevention of medication harms. Older avacopan advice requires the 2026 corrections explained below.
- GPA often affects the upper airway, lungs and kidneys; symptoms in one area do not assess every organ.
- ANCA supports assessment but cannot diagnose GPA alone.
- Induction, maintenance, damage care and medication safety have distinct goals.
- Avacopan advice changed in 2026; consult the specialist about jurisdiction-specific decisions.
Table of contents
- Evidence summary
- What GPA is: symptoms and older names
- How it works and how diagnosis is established
- Treatment: induction, maintenance and 2026 changes
- Supplement and lifestyle evidence
- What works and what remains uncertain
- Risks, side effects and urgent warning signs
- Interactions and situations needing extra care
- Who needs assessment
- Clinician-led treatment and practical follow-up
- Animal and in vitro evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
The practical priority is to recognize the clinical pattern and assess threatened organs. The NHLBI overview describes how vessel inflammation can impair blood supply and damage tissues. A reassuring symptom in one organ cannot document the state of the lungs or kidneys.
| Question | Assessment | Limit |
|---|---|---|
| ANCA result | Useful supporting evidence | Positive alone does not confirm GPA; negative does not exclude all cases. |
| Kidney disease | Urine and kidney-function assessment matter | Inflammation can be clinically quiet. |
| Treatment | Induction and maintenance have different goals | Guideline recommendations are attributed; company-funded efficacy is excluded. |
| Avacopan | Check current local decisions | 2026 US, EU and UK positions differ. |
| Supplements | No established replacement role | A deficiency indication is separate from disease control. |
No survival or relapse percentage from a selected study is used to predict an individual outcome. A guide can explain the decisions while a treating team must establish the diagnosis and the plan.
What GPA is: symptoms and older names
GPA belongs to the ANCA-associated vasculitis family, alongside microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis. The diagnoses share features but are not interchangeable. A historical report using “Wegener’s” may refer to GPA; retain the actual report for review rather than discarding it because the name changed.
The NHS GPA guide describes persistent nasal/sinus trouble, nosebleeds, ear/hearing symptoms, eye problems, breathlessness and kidney findings. Any one of these is common in other illnesses. Their persistence, combination and associated abnormalities determine whether vasculitis assessment is appropriate.
Localized upper-airway symptoms can cause considerable disability even without an immediately life-threatening feature. Eye or airway involvement can also require urgent specialist attention. Ask which manifestation is inflammation, infection, structural damage or another condition; the answer can change treatment substantially.
How it works and how diagnosis is established
The initiating cause is not fully explained. The NHLBI cause discussion describes immune, environmental, infection and medicine-related contexts across vasculitis. These are possible mechanisms and alternatives, not proof that a particular infection or exposure caused one person’s GPA.
Assessment combines the history, examination, blood/urine studies, imaging and selected tissue sampling. NHLBI diagnostic context. A biopsy should answer a specific question; sampling limitations and prior treatment affect what a result can establish.
The EULAR original supports interpreting PR3/MPO ANCA with the clinical picture and considering alternatives such as infection or medicine-associated disease. Biopsy can help distinguish active disease from damage, but urgent treatment should not always wait when organ injury is advancing.
Ask the team which findings establish GPA and which remain uncertain. A positive antibody, an abnormal chest scan and a kidney biopsy are different pieces of evidence. Keeping their dates together helps a new specialist understand the reasoning.
Treatment: induction, maintenance and 2026 changes
The ACR/VF original guideline describes glucocorticoids with rituximab or cyclophosphamide for severe GPA/MPA, and a distinct methotrexate-based approach for suitable nonsevere GPA. These are attributed clinical options; organ threat and toxicity determine suitability. Nonsevere does not mean that symptoms can be ignored.
The newer 2025 BSR original recommendations favor rituximab or cyclophosphamide for active GPA/MPA, including non-organ-threatening presentations. This differs from the dated ACR nonsevere-GPA approach. Guidance is not uniform; ask which framework fits the actual organ findings and risks. BSR’s older avacopan advice also requires the 2026 correction below.
The NHS guide distinguishes an initial phase to control disease from maintenance intended to reduce relapse. Procedures, hearing/eye care or kidney support can address consequences rather than immune activity itself. Ask which problem each intervention is intended to solve.
Avacopan (Tavneos/Avacopan Vifor) needs a separate 2026 safety and regulatory discussion. Older guidance and patient pages predate major concerns about the trial data. The June 2026 indexed retraction record confirms retraction of the pivotal NEJM report; this guide adopts none of its efficacy results.
| Jurisdiction | Verified position at review | Practical distinction |
|---|---|---|
| United States | FDA proposed withdrawal in April 2026 | A proposal and hearing process are not a completed US withdrawal. |
| European Union | European Commission revoked authorization August 4, 2026 | A completed EU decision; existing treatment requires professional review. |
| United Kingdom | MHRA suspended new-patient use/supply September 1, 2026 | Existing-patient supply only during managed withdrawal; March 1, 2027 revocation is intended, not already completed. |
Ask the prescribing specialist promptly about your local position and alternatives. The UK decision explicitly advises existing patients against stopping without specialist advice. These jurisdiction-specific decisions should not be condensed into a claim that the medicine has already been withdrawn everywhere.
Supplement and lifestyle evidence
No independently cleared human evidence in the reviewed sources establishes a supplement as a substitute for vasculitis treatment or as prevention of lung or kidney injury. Correcting a deficiency or supporting bone health during glucocorticoid treatment is a separate clinical question.
The NCCIH supplement guidance describes interactions, incomplete safety information and evidence gaps. “Anti-inflammatory” marketing is not a demonstrated outcome such as preserved kidney function. Report supplements before treatment changes and before procedures.
The NHLBI living-with guidance supports coordinated follow-up and practical care. Nutrition, smoking avoidance, rehabilitation and emotional support can help daily life, while organ disease still requires its own assessment. Activity goals should account for breathlessness, weakness and the current treatment phase.
What works and what remains uncertain
A useful assessment separates active disease, lasting damage and treatment toxicity. The French recommendations describe this distinction. A persistently damaged organ may need rehabilitation or supportive care even after inflammation settles; a new abnormality requires reassessment rather than an assumption of old damage.
GPA can relapse, which is why ongoing review matters. Vasculitis Foundation context. Remission, improved function and freedom from medication are different outcomes. A single symptom improvement does not prove that all threatened organs are protected.
Treatment evidence does not answer every duration or sequencing question. An established clinical role is not proof that one brand is independently superior. Ask what objective signs will be followed and what finding would justify a change, especially when a medicine has substantial risks.
The NHLBI treatment overview includes organ-directed care and selected procedures. A scan, infusion or operation should have a stated purpose and follow-up plan. An intervention with a technical success is not automatically a complete recovery from prior injury.
Risks, side effects and urgent warning signs
Severe breathing difficulty, coughing up significant blood, new stroke symptoms or collapse need emergency care. NHLBI complication guidance. A known vasculitis diagnosis does not establish the cause of every emergency; bleeding, infection and another acute illness can require different management.
Report fever or acute illness during immune-suppressing treatment promptly. The Liverpool cyclophosphamide leaflet describes infection, low blood-count, bladder and reproductive risks. Unexplained bleeding, urinary symptoms or unrelieved breathlessness require professional advice. Its local dosing and monitoring instructions are not copied as a universal regimen.
Glucocorticoids can affect bone, blood sugar, mood, sleep and infection risk. NHS prednisolone safety information. A monitoring plan should address medicine toxicity alongside vessel inflammation. Symptoms should not automatically be attributed to a harmless treatment effect.
The FDA March 2026 avacopan safety alert reports serious liver injury, including fatal cases. Yellow eyes/skin, dark urine, pale stools, itching or abdominal pain while taking it warrant prompt medical contact. Spontaneous reports establish a safety concern; they do not yield a reliable personal risk percentage.
New visual loss, marked eye pain or noisy/difficult breathing deserves urgent professional assessment. NHS organ-symptom guidance. Do not wait for a routine blood test to explain a potentially threatened eye or airway.
Interactions and situations needing extra care
Review infection history, hepatitis exposure, vaccine timing and all medicines with the treating team. The French original recommendations discuss infection/reactivation risks under immunosuppression. A past infection, an active infection and a negative screening result have different implications; no single screening test clears every future risk.
NSAIDs, aspirin and supplements can complicate prednisolone treatment. NHS interaction advice. Kidney impairment or gastrointestinal problems can further change the appropriateness of an over-the-counter pain medicine. Bring ingredient lists and prescribed medicines rather than relying on a product’s “natural” label.
Methotrexate can interact with trimethoprim/co-trimoxazole and other medicines. NHS medicine-safety guidance. A specialist may need an infection-prevention plan alongside immune treatment, but that plan must account for these interactions. Do not add or stop prophylaxis by applying a general online rule.
Discuss pregnancy, contraception and fertility preservation when relevant. Cyclophosphamide safety information. Planning must account for disease activity, previous exposure and organ urgency. A blanket instruction to stop every immune medicine before pregnancy can itself leave a serious disease untreated.
Who needs assessment
Persistent upper-airway illness combined with unexplained chest, kidney, eye, skin or nerve findings warrants evaluation. NHLBI organ-pattern guidance. Many more common conditions can cause these symptoms; the purpose of assessment is to distinguish them, not to diagnose GPA from a checklist.
Kidney inflammation can occur without obvious symptoms. Vasculitis Foundation kidney warning. Planned urine and kidney-function review may therefore be relevant even when a person feels better. Visible urine changes are useful to report but are not a complete monitoring method.
Established GPA needs reassessment for new symptoms during remission, during a taper or after a change in treatment. Bring the prior diagnosis evidence, medication history and recent test results. Say when a change began and how it affects function, rather than reporting only that the vasculitis feels “active.”
Clinician-led treatment and practical follow-up
Agree on emergency contacts and on who coordinates rheumatology, kidney, lung, ear/nose/throat and eye care. Record each medicine’s purpose, required monitoring and relevant past adverse effects. Shared records matter when treatment decisions span several departments.
Prednisolone used for a prolonged period should not be stopped suddenly. NHS stopping guidance. A taper is a clinical plan rather than a test of willpower; illness, disease activity and treatment intolerance can require its review.
If methotrexate is prescribed for inflammatory disease, administration is generally weekly; a daily-dosing error requires urgent advice. NHS administration safety. This statement does not supply a dose or establish that methotrexate fits every GPA presentation.
Discuss rehabilitation, work adjustments, sleep and emotional support alongside organ monitoring. A useful follow-up addresses daily function as well as laboratory results, and should make clear which new symptom requires an immediate call.
Animal and in vitro evidence
Cell and animal work can explore neutrophils, ANCA and inflammatory pathways. Such mechanisms can generate treatment hypotheses without establishing human benefit. They cannot determine a person’s diagnosis or show that a supplement prevents kidney injury.
This guide’s verdict requires relevant human clinical outcomes, appropriate safety data and traced funding. A biomarker change, an experimental lesion or a plausible immune mechanism is not interchangeable with remission, hearing preservation or avoidance of organ failure. Manufacturer-sponsored efficacy and the retracted avacopan results are excluded.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 33 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Original ACR/VF, EULAR, BSR and French guideline texts and their printed financial declarations were checked. They contain society/public support and author company relationships; some French studies received Roche-supplied drug, making those underlying product outcomes Tier 4 and excluded. BSR declares no external project funding, with society logistical support; that does not erase author ties or the society’s commercial income routes. Vasculitis Foundation accounts and named sponsorship were traced. Public education does not clear underlying trials. FDA, EMA and MHRA have industry-fee funding and public accountability; their current safety/legal records are attributed by jurisdiction. Promotional links and retracted avacopan efficacy are excluded.
Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| ACR/VF: original 2021 AAV management guideline | ACR/VF support. Printed declarations include Langford BMS fees and BMS/GSK/Genentech research; Merkel multiple company fees/research and UpToDate royalties; Stone Roche/Genentech fees; Dua AbbVie/ChemoCentryx fees; Grayson/Sule patents and Sundel royalties. | United States-led panel; international academic/clinical authors | Tier 2 — society support and mixed author ties | B for attributed guidance; C for independent efficacy — sparse/conditional evidence and unverified underlying financial chains. |
| EULAR: original 2022 AAV update, published 2023/2024 | EULAR support; Jayne NIHR support plus multiple company fees; Little Vifor/ChemoCentryx funding/fees; Merkel company fees/research and Kyverna stock options; other company grants/fees and some no-conflict declarations. | International European/US panel; Swiss EULAR; UEA original repository UK | Tier 2 — mixed public/society and author commercial ties | B for attributed framework; C for independent efficacy — older avacopan recommendations require 2026 regulatory correction; underlying trials mixed. |
| Terrier et al.: original French recommendations, 2020/2021 correction | FAI2R funded by French National Health Ministry. Original names author Roche/AstraZeneca/GSK and other company fees/research; Puéchal academic studies received Roche-supplied rituximab. Full supporting institutional budgets unresolved. | France-led; GFEV editorial responsibility; international collaborators | Tier 2 — public network funding and mixed author relationships; supplied-drug underlying trials Tier 4 | B for dated attributed clinical framework; C for independent outcomes — consensus and uncleared included trials. |
| Vasculitis Foundation: GPA written guide (February 2024) | US charity receives contributions, corporate-membership fees and other income. Its own awareness fundraising page names Amgen and AstraZeneca as 2025 sponsors; page-specific allocation and full donor chain not established. | United States; charity headquarters Kansas City, Missouri | Tier 3 — advocacy, fundraising and corporate-support routes | B provisional for patient education; C for treatment-effect claims — specialist input, dated simplification and donor/mission interests. |
| NHS: GPA guide (May 2024) | DHSC-funded NHS website; its policy rejects advertising and corporate sponsorship. Page-author disclosures and all underlying trial finances not supplied. | United Kingdom; England public patient information | Tier 1 provisional for educational role | B — clinical sign-off and public-service accountability; policy is not an audit of underlying trials. |
| BSR: original 2025 AAV management recommendations | No external project funding declared; BSR logistical support. Printed author disclosures include CSL Vifor/AstraZeneca/GSK/Lilly/Pfizer and other company research, consultancy, honoraria or sponsorship. Full institutional chains unresolved. | United Kingdom-led panel; BSR London; original university repository Cambridge | Tier 2 — mixed author/company ties and society support | B for attributed framework; C for independent efficacy — recommendations differ from older guidance; underlying trials not cleared. |
| BSR: original sponsorship and partnership offers | Corporate conferences, branded sessions, educational/content partnerships, research support and journal adverts/reprints/supplements offered. Page names Lilly UK partnership testimonial. Full latest accounts and project allocation not retrieved. | United Kingdom; official site identifies Bride House, 18–20 Bride Lane, London | Tier 3 — professional society with commercial revenue routes | B for direct institutional disclosure; fundraising and specialty incentives, incomplete realized-income ledger. |
| ACR: corporate support opportunities | Paid grants, advertising, sponsorship and commercial data-program access offered. Complete current accounts and guideline-project allocation not audited. | United States; Atlanta professional society | Tier 3 — professional/commercial revenue routes | B for institutional arrangements; specialty and fundraising incentives. |
| Vasculitis Foundation: audited FY 2024–25 accounts | Accounts identify contributions, corporate-membership revenue, conference fees and investments. All corporate payers and earmarked allocations are not specified. | United States; Kansas City, Missouri nonprofit | Tier 3 — charity corporate-income route | B for dated accounting disclosure — financial audit does not certify clinical independence; later income and source allocations unresolved. |
| Vasculitis Foundation: awareness fundraising sponsors | Organization explicitly thanks Amgen and AstraZeneca for 2025 Vasculitis Awareness Month sponsorship. This is a named awareness-program tie, not proof of sponsorship of each guideline or patient page. | United States; advocacy charity | Tier 3 — commercial program sponsorship | B for direct named disclosure; organization fundraising interests and program-specific limits. |
| EULAR: membership/dues | Society charges membership fees, including supporting companies; full project-specific allocation unresolved. | Switzerland; current office Zurich | Tier 3 — professional society revenue | B for institutional disclosure; fundraising/specialty interests. |
| EULAR: corporate membership list | Original names AbbVie, Amgen, AstraZeneca, GSK, Pfizer, Roche and other companies; membership is not proof of direct funding of a specific guideline. | Switzerland; multinational corporate members | Tier 3 — documented company membership | B for named relationships; amounts/control and allocation unresolved. |
| NHLBI: vasculitis overview (May 2023) | US congressional public funding; NHLBI also accepts authorized gifts. Page-specific donors and complete underlying study finances not reported. | United States; NIH/NHLBI federal jurisdiction | Tier 1 provisional for educational role | B — public accountability; educational simplification, institutional interests and dated evidence remain. |
| NHLBI: causes (May 2023) | US congressional public funding; NHLBI also accepts authorized gifts. Page-specific donors and complete underlying study finances not reported. | United States; NIH/NHLBI federal jurisdiction | Tier 1 provisional for educational role | B — public accountability; educational simplification, institutional interests and dated evidence remain. |
| NHLBI: symptoms (May 2023) | US congressional public funding; NHLBI also accepts authorized gifts. Page-specific donors and complete underlying study finances not reported. | United States; NIH/NHLBI federal jurisdiction | Tier 1 provisional for educational role | B — public accountability; educational simplification, institutional interests and dated evidence remain. |
| NHLBI: diagnosis (May 2023) | US congressional public funding; NHLBI also accepts authorized gifts. Page-specific donors and complete underlying study finances not reported. | United States; NIH/NHLBI federal jurisdiction | Tier 1 provisional for educational role | B — public accountability; educational simplification, institutional interests and dated evidence remain. |
| NHLBI: treatment (May 2023) | US congressional public funding; NHLBI also accepts authorized gifts. Page-specific donors and complete underlying study finances not reported. | United States; NIH/NHLBI federal jurisdiction | Tier 1 provisional for educational role | B — public accountability; educational simplification, institutional interests and dated evidence remain. |
| NHLBI: living with vasculitis (May 2023) | US congressional public funding; NHLBI also accepts authorized gifts. Page-specific donors and complete underlying study finances not reported. | United States; NIH/NHLBI federal jurisdiction | Tier 1 provisional for educational role | B — public accountability; educational simplification, institutional interests and dated evidence remain. |
| NHLBI: budget and gift authority | Congressional budget process and authorized donations/bequests documented by NHLBI. Individual gift donors not audited. | United States; federal institution | Tier 1 for institutional context | B — direct institutional provenance; self-report and mission incentives remain. |
| NHS: prednisolone side effects | DHSC-funded NHS website; its policy rejects advertising and corporate sponsorship. Page-author disclosures and all underlying trial finances not supplied. | United Kingdom; England public patient information | Tier 1 provisional for educational role | B — clinical sign-off and public-service accountability; policy is not an audit of underlying trials. |
| NHS: prednisolone use and stopping (February 2022) | DHSC-funded NHS website; its policy rejects advertising and corporate sponsorship. Page-author disclosures and all underlying trial finances not supplied. | United Kingdom; England public patient information | Tier 1 provisional for educational role | B — clinical sign-off and public-service accountability; policy is not an audit of underlying trials. |
| NHS: prednisolone interactions (February 2022) | DHSC-funded NHS website; its policy rejects advertising and corporate sponsorship. Page-author disclosures and all underlying trial finances not supplied. | United Kingdom; England public patient information | Tier 1 provisional for educational role | B — clinical sign-off and public-service accountability; policy is not an audit of underlying trials. |
| NHS: methotrexate use (March 2023) | DHSC-funded NHS website; its policy rejects advertising and corporate sponsorship. Page-author disclosures and all underlying trial finances not supplied. | United Kingdom; England public patient information | Tier 1 provisional for educational role | B — clinical sign-off and public-service accountability; policy is not an audit of underlying trials. |
| NHS: methotrexate interactions (March 2023) | DHSC-funded NHS website; its policy rejects advertising and corporate sponsorship. Page-author disclosures and all underlying trial finances not supplied. | United Kingdom; England public patient information | Tier 1 provisional for educational role | B — clinical sign-off and public-service accountability; policy is not an audit of underlying trials. |
| NHS website: content and funding policy | DHSC funding; website states no advertising or corporate sponsorship. Full staff disclosure register not retrieved. | United Kingdom; NHS England website | Tier 1 provisional for institution | B — explicit editorial safeguards; institutional self-report does not clear every cited trial. |
| NCCIH: using dietary supplements wisely | US federal NIH/NCCIH education; page-specific external support and all included-study financial chains not audited. | United States; NIH federal jurisdiction | Tier 1 provisional for safety context | B — public accountability and explicit evidence gaps; institutional interests and untraced trial sponsors. |
| Liverpool University Hospitals: cyclophosphamide leaflet | Public NHS provider; actual FY 2024/25 accounts show NHS commissioner income, private-patient/non-NHS income, research contracts and capital donations. This leaflet’s payer allocation and author industry interests not traced. | United Kingdom; Liverpool NHS Foundation Trust, England | Tier 2 provisional — public provider with mixed income; page chain unverified | B provisional for safety — clinical duty; provider, research and budget incentives. No outcome ranking. |
| Liverpool University Hospitals: FY 2024/25 original accounts | Original notes 3/4 document NHS/ICB patient-care income, private/non-NHS income, research/education income and capital grants/donations; named Marina Dalglish Appeal contribution for robotic equipment is separate from this leaflet. | United Kingdom; English NHS Foundation Trust | Tier 2 — public provider with mixed revenue | B for dated accounting disclosure; full donor/research payer list and leaflet attribution unresolved. |
| FDA: April 2026 Tavneos withdrawal proposal | FDA public budget and regulated-industry user fees; review is a regulator statement, not manufacturer-authored efficacy. Complete case-specific staff conflicts not audited. | United States; FDA federal jurisdiction; ChemoCentryx owned by Amgen | Tier 2 — industry-fee regulator | B — legal mandate and public record; proposal is distinct from completed US withdrawal. |
| FDA: March 2026 avacopan liver-injury safety alert | FDA public budget and regulated-industry user fees; review is a regulator statement, not manufacturer-authored efficacy. Complete case-specific staff conflicts not audited. | United States; federal drug regulator | Tier 2 — public/industry-fee funding | B — regulator safety accountability; spontaneous reports do not supply population incidence. |
| FDA: January 2026 funding overview | Federal budget authorization and regulated-industry user fees; source-specific regulator staff interests not audited. | United States; federal drug/device regulator | Tier 2 — regulated-industry fees | B — legal mandate and fiscal disclosure; political, budget and industry-access interests. |
| EMA: Tavneos referral and final August 2026 EU decision | EU agency budget relies heavily on medicine-company regulatory fees plus EU/EEA contributions; own original 2026 budget checked. Complete staff/case conflicts not independently audited. | Netherlands headquarters Amsterdam; European Union/EEA regulatory remit | Tier 2 — regulated-industry fees | B — public/legal accountability; funding dependence and review limits. |
| EMA: original adopted 2026 budget | Revenue notes explicitly identify pharmaceutical/regulatory service fees, EU/EEA contributions and other revenue; planned budget is not final realized income. | Netherlands; EU agency, Amsterdam official address | Tier 2 — substantial industry-fee route | B — direct budget provenance; political/fiscal interests and budget-versus-outturn distinction. |
| PubMed: June 2026 NEJM avacopan retraction identity | NLM federal bibliographic service; underlying journal is Massachusetts Medical Society. Notice-specific editor financial form and full journal accounts unresolved. No trial efficacy adopted. | United States; NLM registry and US journal; trial multinational | Tier 1 provisional for registry identity; issuer finances unverified | B for date/DOI/retracted-publication identity; metadata is not a review of all financial ties. |
| MHRA: September 2026 UK avacopan decision | UK regulator receives statutory pharmaceutical-industry fees, customer charges and DHSC grant-in-aid. Own FY 2025/26 accounts checked; complete case-specific staff interests unresolved. | United Kingdom; MHRA, 10 South Colonnade, Canary Wharf, London | Tier 2 — regulated-industry fees and public funding | B — legal/public safety accountability; fiscal/industry dependence and case-specific disclosure gaps. |
| MHRA: original FY 2025/26 report and accounts | Financial review identifies statutory industry fees, non-statutory customer income, research grants/services, CPRD data licensing and DHSC grant-in-aid. This is realized FY 2025/26 reporting, distinct from a planned budget. | United Kingdom; official accounts identify London headquarters | Tier 2 — industry-fee/public regulator funding | B for dated financial provenance; institution self-report and agency-level income do not clear case-specific conflicts. |
Frequently asked questions
Is Wegener’s granulomatosis the same as GPA?
GPA is the current name; older reports may use Wegener’s granulomatosis. The clinical diagnosis still needs its supporting evidence.
Does a positive ANCA prove GPA?
No. Antibody results need clinical interpretation, assessment for alternatives and appropriate organ investigations.
Can kidneys be affected without symptoms?
Yes. Feeling well does not replace planned urine and kidney-function assessment.
Is avacopan already withdrawn everywhere?
No. At this review, EU revocation is completed, the US has a withdrawal proposal, and the UK has new-patient suspension with managed existing-patient withdrawal and intended later revocation.
Does remission mean every symptom disappears?
Not necessarily. Lasting damage, treatment effects or another condition can need separate care.
Sources and funding notes
Original 2021 ACR/VF, accepted EULAR 2022 (published 2023/2024), 2025 BSR and French original/correction were opened with printed financial declarations. The newer BSR framework differs from ACR2021 in some treatment choices. Older avacopan wording is superseded by 2026 regulator records: FDA withdrawal proposal, completed EU revocation, and UK new-patient suspension/managed withdrawal before intended March 2027 revocation. Retraction identity/text was read in PubMed; full NEJM notice and separate author forms were unavailable. BSR’s own sponsorship page was retrieved; full latest accounts could not be accessed. NHS medicine pages with past review dates are explicitly dated. No effect percentage, personal dose, threshold or universal treatment duration is supplied.
- ACR/VF: original 2021 AAV management guideline — Dated clinical framework; no cleared drug-effect percentages.
- EULAR: original 2022 AAV update, published 2023/2024 — Assessment and disease-treatment distinctions; avacopan advice superseded by current jurisdiction-specific records.
- Terrier et al.: original French recommendations, 2020/2021 correction — HBV-associated PAN distinctions, assessment and safety context; sponsored outcomes excluded.
- Vasculitis Foundation: GPA written guide (February 2024) — Symptoms, organ pattern and follow-up context only; older avacopan text and product-promotional links are not adopted.
- NHS: GPA guide (May 2024) — Ear/nose, eye and organ assessment context; avacopan treatment text predates 2026 regulatory changes and is not adopted.
- BSR: original 2025 AAV management recommendations — 2025 treatment/service framework; avacopan advice requires 2026 regulatory correction.
- BSR: original sponsorship and partnership offers — Society income routes and headquarters; no proof of a named company funding the 2025 project.
- ACR: corporate support opportunities — Revenue model only.
- Vasculitis Foundation: audited FY 2024–25 accounts — Institutional funding model only.
- Vasculitis Foundation: awareness fundraising sponsors — Named commercial relationship only.
- EULAR: membership/dues — Financial context only.
- EULAR: corporate membership list — Named institutional commercial ties only.
- NHLBI: vasculitis overview (May 2023) — Disease-family definition and vessel-size context; not cleared treatment trials.
- NHLBI: causes (May 2023) — Possible triggers and secondary causes; not an individual causal diagnosis.
- NHLBI: symptoms (May 2023) — Organ-specific manifestations and complications.
- NHLBI: diagnosis (May 2023) — Clinical, blood, urine, biopsy and imaging assessment; subtype-specific accuracy not assumed.
- NHLBI: treatment (May 2023) — Attributed general treatment context, not a comparative efficacy verdict.
- NHLBI: living with vasculitis (May 2023) — Follow-up, pregnancy planning and emergency complications; individual risks differ.
- NHLBI: budget and gift authority — Funding trace, not outcome evidence.
- NHS: prednisolone side effects — Infection, bone, metabolic and mood risks; medicine safety, not disease-specific efficacy.
- NHS: prednisolone use and stopping (February 2022) — Clinician-directed tapering and adrenal safety; stated review date has passed.
- NHS: prednisolone interactions (February 2022) — NSAID/aspirin and supplement cautions; dated general medicine context.
- NHS: methotrexate use (March 2023) — Weekly inflammatory-disease administration safety and monitoring; no personal dose.
- NHS: methotrexate interactions (March 2023) — Antibiotic, NSAID, supplement and vaccine review; stated review date has passed.
- NHS website: content and funding policy — Website funding and editorial safeguards only.
- NCCIH: using dietary supplements wisely — Safety and interaction limits, not proof of vasculitis efficacy.
- Liverpool University Hospitals: cyclophosphamide leaflet — Blood-count/bladder/infection/fertility safety; local instructions not a universal regimen.
- Liverpool University Hospitals: FY 2024/25 original accounts — Own provider funding route, not generic NHS branding.
- FDA: April 2026 Tavneos withdrawal proposal — Current FDA proposal, hearing process and clinical discussion advice.
- FDA: March 2026 avacopan liver-injury safety alert — Attributed urgent liver-injury warnings; no numerical risk estimate.
- FDA: January 2026 funding overview — Regulator finance context only.
- EMA: Tavneos referral and final August 2026 EU decision — EU revocation, trial-data concerns and clinician-managed alternatives; not a universal global status.
- EMA: original adopted 2026 budget — Regulator funding and HQ only.
- PubMed: June 2026 NEJM avacopan retraction identity — Confirms June 29, 2026 retraction DOI 10.1056/NEJMe2608684.
- MHRA: September 2026 UK avacopan decision — UK new-patient suspension and managed existing-patient withdrawal; intended future revocation is not a completed decision.
- MHRA: original FY 2025/26 report and accounts — Own regulator finance and headquarters trace only.
Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.